Pomalyst and Bendamustine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pomalyst (pomalidomide) and Bendamustine (bendamustine). Common drug interactions include acute respiratory failure among females and neutrophil count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Pomalyst and Bendamustine. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.

What is Bendamustine?

Bendamustine has active ingredients of bendamustine. eHealthMe is studying from 9,508 Bendamustine users. Check the latest studies of Bendamustine.

On Jul, 24, 2026

22 people who take Pomalyst and Bendamustine together, and have interactions are studied.

Pomalyst and Bendamustine drug interactions.

What are the common drug interactions of Pomalyst and Bendamustine, by gender? *:

female:

Acute respiratory failure
Pneumonia viral
Pain
Asthenia (weakness)
Dyspnoea exertional (breathlessness or shortness of breath)
Fatigue (feeling of tiredness)
Neutropenia (an abnormally low number of neutrophils)
Plasma cell myeloma (cancer that begins in plasma cells)
White blood cell count decreased

male:

Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
White blood cell count decreased
Acute myocardial infarction (acute heart attack)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Muscular weakness (muscle weakness)
Pain
Adverse event
Muscle spasms (muscle contraction)
Fall

What are the common drug interactions of Pomalyst and Bendamustine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Acute respiratory failure
Pneumonia viral
Death
Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Muscular weakness (muscle weakness)
Pain
Adverse event

60+:

Fall
Pyrexia (fever)
Dyspnoea exertional (breathlessness or shortness of breath)
Fatigue (feeling of tiredness)
Neutropenia (an abnormally low number of neutrophils)
Plasma cell myeloma (cancer that begins in plasma cells)
White blood cell count decreased
Bacteraemia (presence of bacteria in the blood)
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
Hyperuricaemia (level of uric acid in the blood that is abnormally high)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 22 people, 100.00%
Swelling: 2 people, 9.09%
Pain: 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Pomalyst and Bendamustine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously